- 01-12-2011, 09:19 PM
- 01-12-2011, 09:38 PM
There havnt been any real studies done on it for a long period of time but i have used TTA numerous times and ive used SNS TTA-500 multiple times and have never been let down. Works well and ive never had ill side effects when stayin at the proper dosage.
01-12-2011, 11:28 PM
TTA has the benefits of acting as a hypolipidemic agent, mitochondrial proliferation, increased catabolism of fatty acids, antioxidant properties, antinflam action etc. TTA most definitely works, and you will be safe taking it at 1g for 1-2 months (but cycle off please, don't take it non stop). The good thing about the SNS version is it includes electrolytes which help with cramping people experience from TTA.
If you buy it, try a cycle of 1-2 months at 2 caps a day. Just don't forget to cycle off. Cheers.
01-12-2011, 11:49 PM
01-13-2011, 01:56 PM
Department of Clinical Biology, University of Bergen, Norway
Administration of tetradecylthioacetic acid (a 3-thia fatty acid) increases mitochondrial and peroxisomal beta-oxidative capacity and carnitine palmitoyltransferase activity, but reduces free fatty acid and triacylglycerol levels in plasma compared to palmitic acid-treated rats and controls. The decrease in plasma triacylglycerol was accompanied by a reduction (56%) in VLDL-triacylglycerol. Prolonged supplementation of tetradecylthioacetic acid caused a significant increase in lipogenic enzyme activities (ATP-citrate lyase and acetyl-CoA carboxylase) and diacylglycerol acyltansferase, but did not affect phosphatidate phosphohydrolase. Plasma cholesterol, LDL- and HDL-cholesterol levels were reduced. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase activity was, however, stimulated in 3-thia fatty acid-treated rats compared to controls. In addition. the mRNAs of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and LDL-receptor were increased. Tetradecylthioacetic acid administration affected the fatty acid composition in plasma and liver by increasing the amount of monoenes, especially 18:1(n-9), mostly at the expense of omega-3 fatty acids. Compared to liver a large amount of tetradecylthioacetic acid accumulated in the heart, and this accumulation was accompanied by an increase in omega-3 fatty acids, particularly 22:6(n-3) and a decrease in omega-6 fatty acids, mainly 20:4(n-6). The results show that the hypolipidemic effect of tetradecylthioacetic acid is sustained after prolonged administration and may, at least in part, be due to increased fatty acid oxidation and upregulated LDL-receptor gene expression. The increase in lipogenic enzyme activities as well as increased 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity, may be compensatory mechanisms to maintain cellular integrity. Decreased level of 20:4(n-6) combined with increased omega-3/omega-6 ratio in cardiac tissue after tetradecylthioacetic acid treatment may have influence on membrane dynamics and function.
Tetradecylthioacetic acid a 3-thia fatty acid, is a novel bioactive compound. Besides being an antioxidant, it changes the plasma profile from atherogenic to cardioprotective
Ziad A. Muna, Lise Madsen, and Rolf K. Berge
Department of Clinical Biology, Division of Biochemistry, University of Bergen, Haukeland University Hospital, N-5021 Bergen, Norway
Tetradecylthioacetic acid (TTA) which can not be ▀-oxidized, lowers plasma VLDL-triacylglycerol (TG) and LDL-cholesterol (Chol). Increased mitochondrial ▀-oxidation with a concomitant decrease in TG synthesis and secretion, seems to be the primary mechanism underlying the hypotriglyceridemic effect not only of TTA but also of w-3 fatty acids as well as fibrates in rats, rabbits, dogs and possibly also in humans. TTA is an inhibitor of HMG-CoA reductase. We have generated results both in vivo and in vitro that present evidence that TTA besides being a lipid lowering agent, also possesses antioxidant properties. First, TTA inhibits the oxidative modification of LDL which is considered as the key step in the formation of foam cells and in initiation and progression of atherosclerotic plaque. Also TTA changes the antioxidant defense system in a beneficial way i.e. glutathion (GSH) is increased, the total antioxidant status is elevated and TBARS are decreased. Second, TTA has an │olive oil▓ effect since the plasma was enriched with oleic acid (18:1 n-9) and a É9-desaturated metabolite of TTA. This was due to upregulation of the hepatic enzyme É9-desaturase gene expression. Third, TTA lowers the plasma homocysteine level and inhibits restenosis. Fourth, TTA reduces the proliferation of smooth muscle cells. In conclusion, TTA is a hypolipidemic drug but also a new antioxidant. This novel bioactive compound is promising as a new therapeutic drug against atherosclerosis as it changes the plasma profile from atherogenic to cardioprotective.
The metabolic syndrome and the hepatic fatty acid drainage hypothesis.
Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA, Skorve J.
Institute of Medicine, The Lipid Research Group, Haukeland University Hospital, University of Bergen, 5021 Bergen, Norway. email@example.com
Much data indicates that lowering of plasma triglyceride levels by hypolipidemic agents is caused by a shift in the liver metabolism towards activation of peroxisome proliferator activated receptor (PPAR)alpha-regulated fatty acid catabolism in mitochondria. Feeding rats with lipid lowering agents leads to hypolipidemia, possibly by increased channeling of fatty acids to mitochondrial fatty acid oxidation at the expense of triglyceride synthesis. Our hypothesis is that increased hepatic fatty acid oxidation and ketogenesis drain fatty acids from blood and extrahepatic tissues and that this contributes significantly to the beneficial effects on fat mass accumulation and improved peripheral insulin sensitivity. To investigate this theory we employ modified fatty acids that change the plasma profile from atherogenic to cardioprotective. One of these novel agents, tetradecylthioacetic acid (TTA), is of particular interest due to its beneficial effects on lipid transport and utilization. These hypolipidemic effects are associated with increased fatty acid oxidation and altered energy state parameters of the liver. Experiments in PPAR alpha-null mice have demonstrated that the effects hypolipidemic of TTA cannot be explained by altered PPAR alpha regulation alone. TTA also activates the other PPARs (e.g., PPAR delta) and this might compensate for deficiency of PPAR alpha. Altogether, TTA-mediated clearance of blood triglycerides may result from a lowered level of apo C-III, with a subsequently induction of hepatic lipoprotein lipase activity and (re)uptake of fatty acids from very low density lipoprotein (VLDL). This is associated with an increased hepatic capacity for fatty acid oxidation, causing drainage of fatty acids from the blood stream. This can ultimately be linked to hypolipidemia, anti-adiposity, and improved insulin sensitivity.
PMID: 15733731 [PubMed - indexed for MEDLINE]
Transient up-regulation of liver mitochondrial thymidine kinase activity in proliferating mitochondria.
Elholm M, Hollňs H, Issalene C, Barroso JF, Berge RK, Flatmark T.
Department of Biochemistry and Molecular Biology, University of Bergen, Norway. firstname.lastname@example.org
Administration of the fatty acid analogue tetradecylthioacetic acid (TTA) to rodents up-regulates peroxisomal and mitochondrial lipid-metabolizing enzymes and induces a proliferation of these organelles in hepatocytes. We show here that male NMRI mice fed a diet containing 0.3% (w/w) TTA revealed a transient two-fold increase in the incorporation of [3H]thymidine into the liver mtDNA followed by a 1.6-fold increase in the content of mtDNA. In addition, a transient three-fold increase in the mitochondrial thymidine kinase (TK2) activity and a slight increase in the DNA polymerase gamma activity was observed, indicating that the TTA induced mitochondrial proliferation is linked to an up-regulation of the mitochondrial thymidine kinase activity.
PMID: 11463171 [PubMed - indexed for MEDLINE]
Proliferation of mitochondria and gene expression of carnitine palmitoyltransferase and fatty acyl-CoA oxidase in rat skeletal muscle, heart and liver by hypolipidemic fatty acids.
Totland GK, Madsen L, Klementsen B, Vaagenes H, Kryvi H, Fr°yland L, Hexeberg S, Berge RK.
Department of Zoology, University of Bergen, Norway. email@example.com
Morphological and biochemical effects were induced at the subcellular level in the skeletal muscle, heart and liver of male rats as a result of feeding with EPA, DHA, and 3-thia fatty acids. The 3-thia fatty acid, tetradecylthioacetic acid (TTA) and EPA induced mitochondrial growth in type I muscle fibers in both the diaphragm and soleus muscle, and the size distribution of mitochondrial areas followed a similar pattern. Only the 3-thia fatty acid induced mitochondrial growth in type II muscle fibers. The mean area occupied by the mitochondria and the size distribution of mitochondrial areas in both fiber types were highly similar in DHA-treated and control animals. Only the 3-thia fatty acid increased the gene-expression of carnitine palmitoyltransferase (CPT)-II in the diaphragm. In the heart, however, the gene expression decreased. In hepatocytes an increase in the mean size of mitochondria was observed after EPA treatment, concomitant with an increase in mitochondrial CPT-II gene expression. Administration of 2-methyl-substituted EPA (methyl-EPA) induced a higher rate of growth of mitochondria than EPA. At the peroxisomal level in the hepatocytes a 3-thia fatty acid, EPA, and DHA increased the areal fraction concomitant with the induction of gene expression of peroxisomal fatty acyl-CoA oxidase (FAO). In the diaphragm, mRNA levels of FAO were not affected by EPA or DHA treatment, whereas gene expression was significantly increased after 3-thia fatty acid treatment. In the heart, both 3-thia fatty acid, EPA and DHA tended to decrease the levels of FAO mRNA. The areal fraction of fat droplets in all three tissue types was significantly lower in the groups treated with 3-thia fatty acid. In the group treated with EPA a lower areal fraction of fat droplets was observed, while the DHA group was similar to the control. This indicates that EPA and DHA have different effects on mitochondrial biogenesis.
PMID: 11071041 [PubMed - indexed for MEDLINE]
The metabolic effects of thia fatty acids in rat liver depend on the position of the sulfur atom.
Gudbrandsen OA, Dyroy E, Bohov P, Skorve J, Berge RK.
The Lipid Research Group, Institute of Medicine, University of Bergen, Haukeland University Hospital, N-5021 Bergen, Norway. firstname.lastname@example.org
The effects on oxidation and composition of fatty acids in rat liver were compared after administration of fatty acids with sulfur substituted in different positions. It has been hypothesized that drugs with hydrophobic backbone have lipid-lowering effects because they are not easily catabolized by mitochondrial beta-oxidation. Thia fatty acids cannot be beta-oxidized when sulfur is in 3-position, but beta-oxidation is possible when sulfur is positioned further from the carboxyl group. To investigate whether catabolism of thia fatty acids would affect their ability to influence lipid metabolism, a series of thia fatty acids were synthesized and administered by oral gavage to male Wistar rats (300 mg/kg bodyweight/day for 7 days). Depending on the position of the sulfur atom and the chain length, the thia fatty acids were beta-oxidized, desaturated and/or elongated, and the accumulated amounts were lower as the sulfur atom were positioned further from the carboxyl group. All thia fatty acids led to high peroxisomal beta-oxidation of endogenous fatty acids, whereas the mitochondrial beta-oxidation was high when sulfur was in 3-position, low when sulfur was in 4-position and similar to controls when sulfur was in 5- or 7-position. The changes in hepatic fatty acid composition were more pronounced when sulfur was positioned close to the carboxyl group. In conclusion, both the position of the sulfur atom and the chain length appear to determine the catabolic fate of thia fatty acids, and the non-beta-oxidizable thia fatty acids were most potent in regulating oxidation and composition of endogenous fatty acids in rat liver.
01-13-2011, 01:58 PM
01-13-2011, 08:12 PM
01-13-2011, 09:59 PM
TTA-500 is a good product. Combine it with RK-125 (Raspberry Ketones) and it makes it even better. I'm using both currently.
01-14-2011, 07:05 AM
01-14-2011, 01:28 PM
01-15-2011, 03:01 AM
Is TTA coming back? Out of stock now.....I used this a couple of years ago with good success....been going back to my roots lately, lol
This message was paid for by the Russians
01-15-2011, 12:52 PM
01-15-2011, 01:03 PM
01-15-2011, 10:53 PM
01-17-2011, 06:29 PM
01-17-2011, 08:43 PM
01-17-2011, 10:11 PM
01-18-2011, 12:17 AM
It would be difficult to match up to what you would get in DCP.
I already like TTA.....wouldnt hurt to see the addition of Dan Shen. Im considering dosing the Dan Shen a little higher but not too much higher.
This message was paid for by the Russians
01-18-2011, 07:36 AM
01-22-2011, 05:35 PM
01-22-2011, 05:39 PM
01-22-2011, 07:16 PM
01-23-2011, 11:39 AM
01-23-2011, 08:35 PM
01-25-2011, 12:15 AM
Serious Nutrition Solutions DAA 3.12 Caps
What happens at month 6, to make it dangerous, that doesn't happen at month 1-5?
Also, has the concept of homeostasis ever been proven legitimate with clinical findings based on blood profiles where DAA is concerned, or any other natural supplement taken for an extended duration?
01-25-2011, 01:05 AM
To give you an answer though - as with most fat loss products/ingredients, the thought is that tolerance can develop over time, and most people feel that it is best to cycle these types of products.
You can also find further information on TTA and cycling from years back from some very intelligent people such as Dsade, Matt Cahill, some of the DS reps when they made their Melting Point, etc.
You seemed to take offense in the other thread by the fact that in the absence of evidence saying that something can be taken safely for indefinate periods of time that we would recomend cycling of things, but that is the stance of most supplement companies.
As I did in the DAA thread, I have attempted to answer your question. If you have any further questions, feel free to ask me in the thread, or by pm.
We are here to to provide top quality products at cost effective prices, and try to help customers to the best of our ability, not argue.
01-26-2011, 12:44 AM
I simply bowed out of the thread because it was obvious where it was going. There is no such this as certainty in supplementation science, that's all I was saying. Dr. D and other members have been using DAA for a very long time and experienced no ill effect.
Anyway, I like both DAA and TTA, I've used and am using one or the other right now and plan to keep doing so for a long time to come. Please, don't be swayed to believe anything less than the truth simply because I have a competing company's acronym attached below my posts.
01-26-2011, 02:43 PM
Just because you dont agree with the directions doesnt make them any less true. I would much rather tell someone not to exceed ___ period of use, and it later be proved that they could have taken it indefinately than to say to take someone indefinately and then it turn out they shouldnt have exceeded a certain period of time. In the case of DAA, it makes logical sense to run it the way people do most products that affect hormone levels, which is by cycling them.
In regards to D or other people running it indefinately, I cannot control how long they run things. That is their right to exercise their personal choice. It still doesnt make it the right way to do it. It doesnt mean its wrong, but doesnt make it right either. And in absence of knowing, I prefer to suggest our customers err on the side of caution.
I would have replied the same, I really didnt even pay attention to you representing another company. Some companies may make certain replies based off things like that, but I focus on what SNS is doing, not other companies, and I treat forum posters all as potential customers whether affiliated with another company or not.
08-21-2011, 01:11 PM
So tta is non stim correct? I'm gonna be logging 3z for Ann innovations in sept- I USUALLY take a pm fat loss product/sleep but the 3z is purely sleep aid so I want to add something to help with overnight leaving... Thinking tta, any thing else I can add as well (non stim obviously ) thanks guys
08-21-2011, 06:37 PM